Peru Certificate of Free Sale (CFS) and High-Surveillance Countries: Evidence Strategy 2026
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
Regulatory information verified as of October 29, 2026
1. Key takeaways
A Certificate of Free Sale (Certificado de Libre Venta, CFS) issued for Peru certifies one fact only: that the product circulates legally in the issuing country. Its evidentiary weight depends on whether the issuing country belongs to the list of Países de Alta Vigilancia Sanitaria (countries of high sanitary surveillance). Listing status raises the credibility tier of the evidence; it does not waive technical documentation obligations, and it does not automatically dissolve the consular legalization chain that authenticates the document. The specific scope of any exemption from legalization is not found in the provisions we have verified and remains a practical estimate — current DIGEMID and Peruvian Ministry of Foreign Affairs publications prevail. In dossier terms, the CFS should be planned as supporting evidence of lawful overseas status, budgeted in time for notarization and legalization, and renewed in step with the Peruvian registration cycle.
2. Legal basis
| Regulation | Number | Publication date | Provisions / key points |
|---|---|---|---|
| Reglamento para el Registro, Control y Vigilancia Sanitaria… | D.S. N° 016-2011-SA | 2011-07-27 | Sanitary registration documentation framework; context for the list of countries of high sanitary surveillance; sanitary registration valid for 5 years |
| Reglamento que establece las Reglas de Clasificación y los Principios Esenciales… | D.S. N° 003-2020-SA | 2020-02-06 | Anexo 1 contains 18 classification rules; a CFS does not replace the conformity argument under the Principios Esenciales |
| Nuevo Texto Único de Procedimientos Administrativos (TUPA) del MINSA | D.S. N° 011-2026-SA | 2026-07-21 | Consolidates procedural requirements, deadlines and fees; CFS submission requirements in the requirement lists follow the current text |
| Modificatoria del D.S. N° 016-2011-SA | D.S. N° 016-2017-SA | 2017-06-07 | Amends documentation articles Art. 124, Art. 125, Art. 127, Art. 130 and others |
| Ley de los Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios | Ley N° 29459 | 2009-11-26 | Capítulo IV (sanitary registration) |
Regulatory information verified as of October 29, 2026.
3. Expert insights
Insight 1: the CFS certifies marketable status, not technical conformity.
A CFS is issued by the competent authority of the issuing country and states that a given product is lawfully marketed and freely sold there. Its object of proof is legal status, not the performance, safety or effectiveness of the device. Its role in the dossier is therefore corroboration of lawful overseas identity, and it cannot substitute for the technical report, risk management or the essential-principles conformity checklist. Submitting a CFS as if it were quality evidence produces a type mismatch in review: the reviewer asks what demonstrates safety and effectiveness, while the CFS answers where the product has legally been sold. The two questions never converge, and the file will be queried on exactly that ground.
Insight 2: the list of countries of high sanitary surveillance is a graded regulatory-trust mechanism.
The lists under D.S. N° 016-2011-SA and DIGEMID publications name countries including France, the Netherlands, the United Kingdom, the United States, Canada, Japan, Switzerland, Germany, Spain, Australia, Denmark and Italy (the list follows official publications). The operating logic is that for jurisdictions whose regulatory output is recognized, domestic review lowers the intensity of duplicate verification. Mechanically this is a reduction in review intensity, not a removal of the review step — listing status influences the weight a reviewer gives to overseas evidence, but it does not touch the obligation to submit local technical documentation. Planning a submission around listing status alone, as though it replaced local evidence, misreads the mechanism.
Insight 3: consular legalization addresses formal authenticity and runs parallel to regulatory trust.
Consular legalization — notarization in the issuing country followed by authentication through diplomatic or consular channels for use in Peru — functions so that an overseas public document is recognized domestically as an authentically signed instrument. It addresses the form of the document, not the substance of the product. Even where the issuing country is on the list, the consistency of the translation, the signing authority, the seal and the date of issuance must still be internally coherent. The specific scope of any legalization exemption is not found in the provisions we have verified and remains a practical estimate; official publications prevail. We therefore do not recommend building a submission on the assumption that listing status equals exemption from legalization.
Insight 4: the time properties of the CFS must be aligned with the re-registration cycle.
A sanitary registration is valid for 5 years, and the re-registration submission window opens 1 year before expiry (D.S. N° 016-2011-SA Art. 7; Ley N° 29459 Art. 11). A CFS that carries no validity statement, or whose validity is shorter than the certificate cycle, creates an evidence gap at re-registration. Statistics derived from the DIGEMID registry, as of 2025-02-14, show 33,109 registration records, 28,819 valid registrations, 6,316 manufacturers, 1,688 registration holders and 68 countries of origin — the concentration of source countries shows that most applicants rely on overseas certificates from a small number of jurisdictions, which makes the continuing validity of the CFS one of the most frequent questions at the re-registration stage.
4. Practical recommendations
- Obtain the CFS from a listed jurisdiction first: check whether the product is already lawfully marketed in listed jurisdictions such as France, Germany, Spain, the United Kingdom, the United States, Canada, Japan or Switzerland before choosing the issuing country (the list follows official publications).
- Verify every element: a CFS should state the product name and model, manufacturer name and address, overseas marketing status or registration number, issuing authority, signatory and date of issuance; for multi-model products, cover the full declared scope through a list annex.
- Bind it to the re-registration calendar: build a 5 years cycle from the date the sanitary registration certificate was granted, and refresh the CFS when the window 1 year before expiry opens, avoiding evidence gaps.
- Prepare the legalization chain on the most conservative reading: until the official scope of any exemption is confirmed, complete the full notarization and consular chain, and match the Spanish translation item by item against the original.
- Do not race the review clock: the time needed to obtain and legalize the CFS must be front-loaded before submission, so that notarization is not attempted inside the 30 working days Observaciones response window.
- Layer the evidence: file the CFS under the lawful overseas identity layer and the technical report and essential-principles checklist under the safety-and-effectiveness layer; the two layers never substitute for each other.
5. Verification checklist
□ It has been confirmed whether the CFS issuing country belongs to the countries of high sanitary surveillance (the list follows official publications)
□ CFS elements have been checked: product and models, manufacturer, marketing status or registration number, issuing authority, signatory and date of issuance
□ It has been confirmed that the CFS does not replace the technical report or the conformity argument under the Principios Esenciales
□ The notarization and consular legalization chain has been prepared on the most conservative reading (any exemption is a practical estimate; official publications prevail)
□ The CFS refresh node has been written into the calendar of the 5 years validity and the re-registration window 1 year before expiry
□ Consistency of the Spanish translation against the original has been verified
□ CFS processing time has been front-loaded before submission, clear of the 30 working days response window
Regulatory information verified as of October 29, 2026.
GRZAN Regulatory Team
GRZAN provides registration support in Peru for manufacturers, importers and authorized representatives, including CFS strategy and legalization handling. Contact: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us